Anna Baukje Lebouille-Veldman

Mrs. Anna Baukje Lebouille-Veldman

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Journal of Neurosurgery: Spine
Verified
Journal Article
Closed access
PDF file
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
DSDylan Spenkelink
Dylan Spenkelink
CACornelia F. Allaart
Cornelia F. Allaart
CVCarmen L. A. Vleggeert-Lankamp
Carmen L. A. Vleggeert-Lankamp
OBJECTIVE: The authors’ objective was to evaluate the association of the Disease Activity Score (DAS) with cervical spine deformity in rheumatoid arthritis (RA) patients during 10-year optimal treatment of systemic disease. METHODS: The authors evaluated radiological and 10-year follow-up (FU) data of the BeSt (BehandelStrategien) trial. In 272 RA patients, atlantoaxial subluxation (AAS), presence of vertical translocation (VT), and subaxial subluxation (SAS) were evaluated. The associations of these deformities with DAS, self-assessed health (determined with the Health Assessment Questionnaire [HAQ]), and erosions of the hands and feet (Sharp–Van der Heijde score) were studied. RESULTS: After 10 years of FU, AAS (> 2 mm neutral position) was observed in 62 patients (23%), AAS (≥ 3 mm in flexion) in 24%, AAS (≥ 5 mm in flexion) in 7%, VT did not occur, and SAS was present in 60 patients (22%). In total, 135 patients (50%) were in remission (DAS < 1.6) at 10 years of FU. No association could be established between AAS and DAS. Patients with cervical spine deformity (AAS > 2 mm and/or SAS) at 10 years had a higher HAQ score at 10 years than patients without cervical spine deformity (HAQ scores of 0.65 and 0.51, respectively, p = 0.04; 95% CI –0.29 to 0.00). CONCLUSIONS: Even though 50% of patients were in remission after 10 years and the BeSt trial was designed to optimize treatment, 40% of patients developed at least mild RA-associated cervical spine deformity and 7% developed significant AAS. This indicates that even in this era of disease-modifying antirheumatic drugs and biologicals, cervical deformity is prevalent among patients with RA and should not be neglected in patient treatment plans and information.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
CACornelia F. Allaart
Cornelia F. Allaart
CVCarmen L. A. Vleggeert-Lankamp
Carmen L. A. Vleggeert-Lankamp
Background. Rheumatoid arthritis (RA) can cause deformity in particularly the craniocervical but also in the lower cervical region. Objectives. The aim of this study is to give an overview of current literature on the association of disease activity score (DAS) and the prevalence and progression of rheumatoid arthritis‐associated cervical spine deformities. Methods. A literature search was done in PubMed, Embase, and Web of Science using a sensitive search string combination (Supplemental File). Studies describing the association between DAS and the incidence and progression of atlantoaxial subluxation, vertical subluxation, and subaxial subluxation were selected by predefined selection criteria, and risk of bias was assessed using a Cochrane checklist adjusted for this purpose. Results. Twelve articles were retrieved, and risk of bias on study level was low to moderate. In the eight longitudinal studies, patients demonstrated high DAS at baseline, which decreased upon treatment with medication: cervical deformity at the end of follow‐up was associated with higher DAS values. The four cross‐sectional studies did not demonstrate a straightforward correlation between DAS and cervical deformity. Deformity progression was evaluated in three studies, but no convincing association with DAS was established. Conclusion. A positive association between prevalence of cervical spine deformities and high disease activity was demonstrated, but quality of evidence was low. Progression of cervical deformity in association with DAS control over time is only scarcely studied, and future investigations should focus on halting of deformity progression.

15 July 2025 in Brain and Spine
Verified
Journal Article
Open access
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
AYAlexander Yearley
Alexander Yearley
TSTimothy R. Smith
Timothy R. Smith
ARAakanksha Rana
Aakanksha Rana
CVCarmen L.A. Vleggeert-Lankamp
Carmen L.A. Vleggeert-Lankamp
While the prevalence of surgery to correct atlantoaxial subluxation (AAS), subaxial subluxation (SAS) and vertical translocation (VT) in patients with rheumatoid arthritis (RA) had declined, cervical deformity is still observed regularly. The objective of this study is to develop a deep learning-based algorithm to predict RA-associated upper cervical spine deformity in patients before or close to RA diagnosis, with the purpose of early risk stratification. Patients with RA in which follow-up cervical MRI studies (at least 3 years apart) were available were identified retrospectively in two tertiary care centers. Patients without definitive deformity at baseline were included in the algorithm. Patients were assessed for RA-associated cervical spine deformity, defined as presence of pannus and/or degeneration of the facet joints of C0-C1 and/or C1-C2 on follow up MRI. Of 3248 patients identified, 220 patients were included in this study, of whom 33 patients developed cervical spine deformity. 153 patients were included for training and sixty-seven for validation of the deep learning-based prediction model. The accuracy of the model was 0.84, with a positive predictive value of 0.56 and a negative predictive value of 0.92. A deep learning model was developed to predict the development of pannus and/or facet joint deformity at the craniocervical junction of patients with RA. Future research should focus on large-scale validation of this model with diverse sites and identifying the role of the subaxial spine in the risk of deformity at the level of the craniocervical junction during the course of disease.

12 December 2024 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
CACyrus Ayubcha
Cyrus Ayubcha
SSSulaiman Sajed
Sulaiman Sajed
COChady Omara
Chady Omara
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
SSShashi B. Singh
Shashi B. Singh
ABAndrew Beam
Andrew Beam
Deep learning has shown significant value in automating radiological diagnostics but can be limited by a lack of generalizability to external datasets. Leveraging the geometric principles of non-Euclidean space, certain geometric deep learning approaches may offer an alternative means of improving model generalizability. This study investigates the potential advantages of hyperbolic convolutional neural networks (HCNNs) over traditional convolutional neural networks (CNNs) in neuroimaging tasks. We conducted a comparative analysis of HCNNs and CNNs across various medical imaging modalities and diseases, with a focus on a compiled multi-modality neuroimaging dataset. The models were assessed for their performance parity, robustness to adversarial attacks, semantic organization of embedding spaces, and generalizability. Zero-shot evaluations were also performed with ischemic stroke non-contrast CT images. HCNNs matched CNNs’ performance in less complex settings and demonstrated superior semantic organization and robustness to adversarial attacks. While HCNNs equaled CNNs in out-of-sample datasets identifying Alzheimer’s disease, in zero-shot evaluations, HCNNs outperformed CNNs and radiologists. HCNNs deliver enhanced robustness and organization in neuroimaging data. This likely underlies why, while HCNNs perform similarly to CNNs with respect to in-sample tasks, they confer improved generalizability. Nevertheless, HCNNs encounter efficiency and performance challenges with larger, complex datasets. These limitations underline the need for further optimization of HCNN architectures. HCNNs present promising improvements in generalizability and resilience for medical imaging applications, particularly in neuroimaging. Despite facing challenges with larger datasets, HCNNs enhance performance under adversarial conditions and offer better semantic organization, suggesting valuable potential in generalizable deep learning models in medical imaging and neuroimaging diagnostics.

22 November 2023 in Lung Cancer
Verified
Journal Article
Open access
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
TTTrent N. Taros
Trent N. Taros
NNNoah L.A. Nawabi
Noah L.A. Nawabi
RMRania A. Mekary
Rania A. Mekary
LPLuke Peng
Luke Peng
JPJohn Phillips
John Phillips
Sotorasib has emerged as a treatment option for patients with KRAS-mutated non-small cell lung cancer (NSCLC); however, its effect in patients with brain metastases is not well described. We assessed the intracranial response of sotorasib in a retrospective case series of patients with brain metastases (BMs) at a single institution. Patients with KRAS-mutated NSCLC with BMs who received sotorasib at Mass General Brigham Hospitals were included. Patients were stratified into three groups: patients with active BM without local therapy within one month of sotorasib initiation (group 1), patients with active BM with local therapy (surgery or radiation) within one month of sotorasib initiation (group 2), and patients with stable BM (group 3). Intracranial progression-free survival (ICPFS) and overall survival (OS) were explored using Kaplan Meier curves that were compared through log-rank test. Thirty patients were included (five in group 1; seven in group 2; 18 in group 3). Mean age at sotorasib initiation was 60 years. Most (67 %) patients had between one and four BMs at sotorasib initiation. Median ICPFS was three months (95 % CI: 0- 7.7) from start of sotorasib for group 1, two months (0-5.7) for group 2, and 15 months (6.0-24.0) for group 3 (p-value = 0.02). Median OS was four months (1.9-6.1) for group 1, six months (0-13.7) for group 2, and 12 months (3.5-20.5) for group 3 (p-value = 0.13). 57 % of patients experienced intracranial progression, including 44 % of patients who had stable BM at sotorasib initiation. While sotorasib may have some intracranial activity, a multidisciplinary approach to BM therapy is still warranted, as are future studies with larger patient samples, controls, and extended follow-up.

13 January 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMahnoor Shafi
Mahnoor Shafi
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
COChady Omara
Chady Omara
NKNamita Kaler
Namita Kaler
JKJohn Kilgallon
John Kilgallon
CVCarmen Vleggeert-Lankamp
Carmen Vleggeert-Lankamp
Background: The effects of smoking on outcomes after spinal spondylodesis remain unclear due to conflicting findings in the existing literature. This meta-analysis aimed to evaluate the association between smoking and clinical as well as radiological outcomes following instrumented spinal fusion, and to examine differences based on smoking status, spinal region, and surgical extent. Methods: PubMed, Embase, and Cochrane were searched up to August 2024 for comparative studies reporting outcomes in smokers and non-smokers undergoing spinal fusion. Extracted outcomes included clinical scores (Oswestry Disability Index [ODI], Neck Disability Index [NDI], Visual Analog Scale [VAS] for pain), fusion rates, pseudoarthrosis, and complications. Pooled percent mean change from baseline and weighted incidences with 95% confidence intervals (CI) were calculated using a random-effects model. Subgroup analyses were performed by spinal region, number of operated levels, and smoking history (current, former, never). Results: Twenty-nine studies involving 6,687 patients were included. In most outcome measures, smokers showed smaller percent improvements than non-smokers. For instance, NDI improved by 42.8% (95% CI: 25.4–60.1%) in smokers vs. 49.7% (32.4–64.0%) in non-smokers; ODI improved by 48.6% (34.7–62.5%) vs. 56.5% (42.6–70.3%); and VAS back pain by 55.0% (29.7–80.2%) vs. 60.5% (35.2–85.7%). Fusion rates were lower in smokers (86.8%) than in non-smokers (95.1%), while pseudoarthrosis was more common in smokers (17.2% vs. 7.3%). Subgroup analyses revealed similar trends across spinal regions and surgical scope. A hierarchical pattern was observed, with never-smokers experiencing the most favorable outcomes, followed by former smokers. Conclusion: In most instances, smokers appeared to experience worse outcomes following instrumented spinal procedures compared to non-smokers, and a hierarchical pattern was notable, with current smokers experiencing the worst outcomes, followed by former smokers compared to never-smokers. Future well-designed studies with proper adjustment for confounding are needed to further confirm these findings.